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Abstract: Kaposi’s sarcoma-associated herpes virus (KSHV) is the etiologic agent for Kaposi’s sarcoma
(KS). The prognostic utility of KSHV and HIV-1 (human immunodeficiency virus) viremia as well as
immunological parameters in clinical management of participants with KS is unclear. The objective
of this study was to investigate viral and immunological parameters as predictors of KS treatment
responses in participants with KS from sub-Saharan Africa (SSA). Plasma KSHV-DNA, HIV-1 viral
load, total anti-KSHV antibody, KSHV-neutralizing antibody (nAb), cytokine/chemokine levels, and
T-cell differentiation subsets were quantified before and after KS treatment in 13 participants with
KS and in 13 KSHV-infected asymptomatic control individuals. One-way analysis of variance and
the Mann-Whitney t-test were used to assess differences between groups where p-values < 0.05
were considered significant. Subjects with patch and plaque KS lesions responded more favorably
to treatment than those with nodular lesions. Pre-treatment and post-treatment levels of plasma
KSHV-DNA, HIV-1 viral load, KSHV-Ab responses, cytokines, and T-cell populations did not predict
the KS treatment response. Elevated KSHV-humoral and cytokine responses persisted in participants
with KS despite a clinical KS response. While patch and plaque KS lesions were more common
among treatment responders, none of the analyzed viral and immunological parameters distinguished
responders from non-responders at baseline or after treatment.
Keywords: Kaposi’s sarcoma; immune responses; neutralizing antibody; cytokine; T-cells; treatment
response; HIV-1; KSHV; sub-Saharan Africa

1. Introduction
Kaposi’s sarcoma (KS), which is a multifocal angio-proliferative sarcoma commonly found on skin
and mucosal surfaces, is caused by the Kaposi’s sarcoma-associated herpes virus (KSHV) or human
herpes virus-8 (HHV-8) [1]. KSHV infection is endemic in sub-Saharan Africa (SSA) with prevalence
as high as 90% in some countries [2–4]. Before the AIDS epidemic, HIV negative African-endemic
KS (EnKS) comprised 4–10% of African adult cancers [5,6]. With the ongoing HIV/AIDS epidemic,
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AIDS-associated/epidemic KS (EpKS) has become the most common cancer in HIV-1 infected African
individuals [7,8].
In developed countries, anti-retroviral therapy (ART) has led to significant decline in KS incidence
in HIV-1 infected individuals, even though recent reports demonstrate that KS still occurs in individuals
with reconstituted CD4+ T-cell counts and a suppressed HIV-1 plasma viral load [9–13]. A similar
decline in KS incidence has not been observed in SSA where KS remains one of the top five cancers
despite of increased ART coverage, uptake, and adherence [9,14,15]. Lack of early disease recognition,
advanced presentation, and lack of effective treatments all contribute to high KS morbidity and
mortality [16–18].
KS treatment in SSA consists of conventional chemotherapy and/or radiotherapy [19–22].
The readily available KS treatments are suboptimal with no curative effects [17,21,23]. First-line
KS treatments employed in developed countries, such as liposomal doxorubicin, alone or in
combination with other drugs, are not readily accessible [24]. With currently available KS treatments,
approximately 50% of African participants with KS achieve some degree of remission [17,21].
Unfortunately, approximately 50% of initially remitting patients experience recurrence within 6 months
post-treatment [21]. Factors that correlate with KS treatment responses are not currently understood.
Since KS is associated with immune suppression, as shown by the high incidence of KS in HIV-1
co-infected individuals, it is possible that immunological differentials before and after KS treatment
would associate with response to treatment. Identification of pre-treatment factors associated with
a response might provide prognostic insight whereas differentials in markers post-treatment might
suggest mechanisms associated with KS control. Therefore, investigation of participants with KS before
and after treatment could be crucial for developing more effective management strategies for KS.
Our recent analysis of immunological responses in participants with EpKS and EnKS prior to
initiation of treatment revealed differentials and potential dysregulation in antibody and cytokine
responses in both participants with EpKS and EnKS [25]. Cytokines associated with increased antibody
production (IL-6, IL-5, and IL-10) as opposed to inflammation and cellular responses [26–29] were
significantly elevated in participants with KS at baseline. Since KS treatment with chemotherapy
or radiotherapy can result in remission, we hypothesized that changes in viral and immunological
parameters before and after treatment would differentiate responders from non-responders. Such
changes could be applied to better stratify patients and improve KS management. However, our
study reveals immune dysregulation persists in treated participants with KS independently of the
therapeutic outcome.
2. Results
2.1. Characteristics of the Study Subjects
To investigate viral and immunological profiles as predictors of the KS treatment response, a total
of 26 individuals (eight KS responders and five non-responders with complete clinical information
and 13 KSHV-infected asymptomatic controls, six HIV-1− and seven HIV-1+ ) were recruited. The two
control groups were comparable in age, gender, CD4 count, and KSHV status (Table 1). Similarly,
there was no statistically significant difference between responders and non-responders in age, gender,
KS lesion morphotype, duration of KS, or ART use and CD4 count at baseline. While the comparison
of CD4 count did not reveal significant differences between groups of controls and participants
with KS, KS non-responders had significantly lower CD4 count when compared to normal controls
(HIV-1− ) (p = 0.03). Participants with KS and controls had comparable duration to ART. Plasma
HIV-1 viremia was also comparable between HIV-1+ controls and participants with KS despite
detectable HIV-1 in a few of the participants with KS (Table 2). The major KS treatment modality was
Adriamycin/Bleomycin/Vinblastine (ABV) chemotherapy except for two cases where radiotherapy
alone was applied to patch and plaque KS lesions on the extremities (Table 1).
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Table 1. Characteristics of the study cohort at baseline.
Kaposi’s Sarcoma-Associated
Herpes Virus (KSHV) Infected
Asymptomatic Controls

Variables

Participants with Kaposi’s
Sarcoma (KS)

p-Values *

KS
Non-Responders
(n = 5)

HIV-1− (n = 6)

HIV-1+ (n = 7)

KS
Responders
(n = 8)

Median age-years
(Range)

49 (33–55)

36 (34–48)

38 (26–57)

44 (39–58)

0.05

Male gender (%)

4 (67)

3 (43)

4 (50)

5 (100)

0.07

Nodular KS lesions (%)

NA

NA

3 (37.5)

4 (80)

0.15

KS duration ** (Range)

NA

NA

12 (1–96)

6 (3–36)

0.68

150 (91–150) ˆ

0.09

Median CD4 count
(Range)

620 (303–1398)

316 (124–675)

377.5
(130–887)

Plasma HIV-1 load
(copies/mL)

NA

BDL

3.5 × 104
(BDL-1.5E5)

1.0 × 104
(BDL-1.5E4)

0.80

Anti-retroviral therapy
(ART) duration ***
(Range)

NA

12 (1–36)

8 (1–36)

24 (0.25–72)

0.52

* Comparison between KS responders and non-responders. ** Self-reported KS duration in months. *** ART duration
in months. Applies for six KS responders only. Two KS responders were HIV negative KS patients. ˆ Comparison
between KSHV infected asymptomatic controls (HIV-1− ) and KS non-responders; p = 0.03. By One-way ANOVA
and Tukey correction. KS—Kaposi’s sarcoma, ART—Antiretroviral Therapy, HIV-1—Human Immunodeficiency
Virus type 1, NA—Not Applicable, BDL—Below detection limit, n—Group sample size, HIV-1-HIV-1 negative,
HIV-1+ HIV-1 positive.

Table 2. Plasma Kaposi’s sarcoma-associated herpes virus (KSHV) and human immunodeficiency
virus (HIV)-1 detection by PCR.
ID

21147
21182
21117
21145
21161
21186
21220
21228
21119
21185
21120
21121
21204

KSHV Virion in Plasma (PCR) (Copies/mL)

CD4 Count (Cells/µL)

HIV-1 Plasma Viral
Copies/mL

Before
Treatment

After
Treatment

Before
Treatment

After
Treatment

Before
Treatment

After
Treatment

Before
Treatment

After
Treatment

+
+
+
+
+
+

+
-

NA
1300
BDL
NA
NA
2100
NA
NA
BDL
NA
BDL
NA
BDL

NA
NA
NA
NA
NA
BDL
NA
NA
NA
NA
NA
NA
NA

887
854
130
422
710
143
167
333
221
178
91
98
150

523
1154
262
370
306
211
NR
353
244
112
482
314
152

NA
NA
3450
BDL
148,000
34,700
BDL
BDL
BDL
BDL
14,500
6310
BDL

NA
NA
BDL
BDL
369,000
BDL
BDL
BDL
BDL
BDL
BDL
BDL
BDL

+ Positive, − Negative, KSHV—Kaposi’s sarcoma herpes virus, NA—Not applicable, BDL—Below detection limit,
HIV-1—Human immunodeficiency virus type 1, Grey shaded—Non-responders, No grey shade —Responders,
NR—Not recorded.

2.2. Similar Viral Profiles in Responders and Non-Responders of KS Treatment
Although KSHV is mostly a cell associated virus, our previous analysis of KSHV detection in a
peripheral blood mononuclear cell (PBMC) revealed a variable detection pattern and lacked association
with anti-KSHV antibody responses [25]. Due to high anti-KSHV antibody responses in KS patients,
we investigated KSHV viremia and antibody responses as predictors of the KS treatment response.
DNase-I treated plasma was used to quantify KSHV virion DNA before and after treatment. Only three
treatment responders and three non-responders had detectable KSHV viremia at baseline, and, when
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detectable, the baseline quantity of KSHV virions in plasma was comparable between responders and
non-responders. However, after KS treatment, only one of six individuals (17%) maintained detectable
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KSHV plasma viremia. The rest became undetectable (Table 2). KSHV viremia was below the detection
21182
1300 Importantly,
NA
854 viremia
1154
NA
NA correlate
limit
for most+ of the plasma
samples.
KSHV
after treatment
did not
21117
+
BDL
NA
130
262
3450
BDL
with
the therapeutic
response.
21145
NA
NA
422
370
BDL
BDL
+
For the participants
controls,
the148000
HIV-1 plasma
viral load
21161
- with EpKS
NA and HIV-1
NA asymptomatic
710
306
369000
+
+ before and
2100after KS BDL
143 CD4+ T-cell
211
34700
BDL+ subjects
was21186
largely undetectable
treatment, and
counts
in the HIV-1
21220
NA
NA
167
NR
BDL
were
similar to
those in-HIV-1− controls
(Table
1). Individuals
with
detectable
plasmaBDL
HIV-1 were
21228
NA
NA
333
353
BDL
BDL
either
on
ART
for
less
than
a
month
(2-individuals)
or
were
experiencing
ART
failure
(1-individual).
21119
+
BDL
NA
221
244
BDL
BDL
21185
- ART use,
- all patients
NA attained
NAHIV-1 viral
178 suppression
112
BDL
BDL who was
With
continued
except
one (21161)
21120
+
BDL
NA
91
482
14500
BDL
switched to the second line ART (Table 2). However, there were no statistically significant
differences
21121
NA
NA
98
314
6310
BDL
in pre-treatment
or
post-treatment
CD4
count
or
HIV-1
plasma
viral
load
between
responders
and
21204
+
BDL
NA
150
152
BDL
BDL
non-responders
or
between
controls
and
participants
with
KS.
Importantly,
none
of
the
variables
in
+ Positive, − Negative, KSHV—Kaposi’s sarcoma herpes virus, NA—Not applicable, BDL—Below
limit,significantly
HIV-1—Human
immunodeficiency
virus
type 1, Grey
shaded—Non-responders,
No analysis.
Tablesdetection
1 and 2 are
associated
with the KS
treatment
response
by logistic regression
grey shade —Responders, NR—Not recorded.

2.3. Humoral Response Differentials between KS Treatment Responders and Non-Responders
2.3. Humoral Response Differentials between KS Treatment Responders and Non-Responders

We previously reported high levels of total anti-KSHV Ab and KSHV-nAb in participants with KS
Wecancer
previously
reported
high
total
anti-KSHV
Abtiters
and of
KSHV-nAb
participants
with
prior to
therapy
[25]. In
thislevels
case,ofwe
tested
whether
these Ab in
responses
at baseline,
or
KS
prior
to
cancer
therapy
[25].
In
this
case,
we
tested
whether
titers
of
these
Ab
responses
at
baseline,
their changes in response to therapy, correlated with the outcome. Neither high nor low Ab titer at
or their changes in response to therapy, correlated with the outcome. Neither high nor low Ab titer
baseline
was associated with the treatment response. However, non-responders had higher anti-KSHV
at baseline was associated with the treatment response. However, non-responders had higher antiAb levels after treatment, which may be indicative of continuing low levels of viral expression without
KSHV Ab levels after treatment, which may be indicative of continuing low levels of viral expression
resulting in detectable plasma viremia (p = 0.01, Figure 1A). High anti-KSHV Ab titers have also been
without resulting in detectable plasma viremia (p = 0.01, Figure 1A). High anti-KSHV Ab titers have
shown
to correlate with KS disease [25,30]. The median KSHV-nAb titers and high or low KSHV-nAb
also been shown to correlate with KS disease [25,30]. The median KSHV-nAb titers and high or low
titers
before
or after
treatment
did not
correlate
the response
outcomeoutcome
(Figure (Figure
1B). Overall,
KSHV-nAb titers
before
or afteralso
treatment
also
did not with
correlate
with the response
despite
undetectable
KSHV plasma
viremia,
humoral
responses
are still
1B). Overall,
despite undetectable
KSHV
plasmaKSHV-specific
viremia, KSHV-specific
humoral
responses
arehigh
still after
treatment
failed but
to differentiate
responders
from non-responders.
high afterbut
treatment
failed to differentiate
responders
from non-responders.

Figure
humoralresponses
responses
before
and
after
treatment.
(A) Immunofluorescence
Figure 1.1. KSHV-specific
KSHV-specific humoral
before
and
after
treatment.
(A) Immunofluorescence
assay
totalanti-KSHV
anti-KSHV
antibody
titers
in plasma
of participants
KS showing
responders
assay for total
antibody
titers
in plasma
of participants
with KSwith
showing
responders
and
non-responders
before before
and afterand
KS treatment
plasma
dilution).plasma
(B) KSHVand
non-responders
after KS (reciprocal
treatmentendpoint
(reciprocal
endpoint
dilution).
neutralizing
antibody (nAb)
titer(nAb)
in plasma
of plasma
participants
with KS showing
and non- and
(B)
KSHV-neutralizing
antibody
titer in
of participants
with KSresponders
showing responders
responders before
and and
afterafter
KS treatment,
presented
as a reciprocal
of 50%
concentration
non-responders
before
KS treatment,
presented
as a reciprocal
ofinhibitory
50% inhibitory
concentration
50). Plasma samples that were nAb-positive at 1:50 dilution were re-assayed in two-fold dilutions
(IC
(IC50 ). Plasma samples that were nAb-positive at 1:50 dilution were re-assayed in two-fold dilutions of
samples
withwith
less than
50% KSHV
of plasma
from
1:50
1:800totodefine
define the
the IC
plasma
from
1:50
toto1:800
IC5050. .KSHV-seropositive
KSHV-seropositive
samples
less than
50% KSHV
neutralization
at
1:50
dilution
were
assigned
a
value
of
30
in
reciprocal
IC
50 plots.
neutralization at 1:50 dilution were assigned a value of 30 in reciprocal IC50 plots.

2.4.Cytokine/Chemokine
Cytokine/Chemokine Levels
Non-Responders
Unaffected
by KS
2.4.
LevelsininResponders
Respondersand
and
Non-Responders
Unaffected
byTreatment
KS Treatment
Werecently
recently reported
reported IL-5,
and
TGF-β
elevation
in both
participants
with with
We
IL-5,IL-10,
IL-10,IL-6,
IL-6,CxCL-10,
CxCL-10,
and
TGF-β
elevation
in both
participants
EpKSand
andEnKS
EnKSwhen
whencompared
compared to
to KSHV-infected
KSHV-infected asymptomatic
asymptomatic controls
EpKS
controlsprior
priortotocancer
cancertherapy
therapy [25].
[25]. In this case, we tested whether baseline cytokine levels (high or low), or temporal changes in
In this case, we tested whether baseline cytokine levels (high or low), or temporal changes in cytokine
cytokine levels over KS treatment, predicted the KS treatment response. The average levels, the high
or low levels of regulatory/inhibitory cytokines, IL-10 and TGF-β, and the anti-inflammatory
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levels over KS treatment, predicted the KS treatment response. The average levels, the high or low levels
of
regulatory/inhibitory
cytokines,
IL-10 and
TGF-β,
and the anti-inflammatory
cytokine,
did
cytokine,
IL-5, did not vary
significantly
between
responders
and non-responders
(FiguresIL-5,
2A–C).
not
vary significantly
responders
non-responders
(Figure with
2A–C).
theresponse
average
Similarly,
the averagebetween
levels of
IL-6 and and
CxCL-10
did not correlate
theSimilarly,
treatment
levels
IL-6 and
CxCL-10
did not
correlate
withand
the CxCL-10,
treatmentbefore
response
(Figure
2A,B). High
versus
(Figureof2A,B).
High
versus low
partitions
of IL-6
or after
treatment,
also did
not
low
partitions
of
IL-6
and
CxCL-10,
before
or
after
treatment,
also
did
not
correlate
with
the
treatment
correlate with the treatment response (Figures 2A,B). Overall, the elevation of inhibitory and
response
2A,B).
the elevation
inhibitory
and regulatory
in participants
regulatory(Figure
cytokines
inOverall,
participants
with KSofafter
treatment
compared cytokines
to non-disease
controls
with
KS after
treatment
compared
to non-disease controls implicates persistent immune dysregulation.
implicates
persistent
immune
dysregulation.

Figure 2.2.Cytokine/chemokine
responses
in plasma
of participants
with Kaposi’s
sarcomasarcoma
(KS) showing
Cytokine/chemokine
responses
in plasma
of participants
with Kaposi’s
(KS)
responders
and non-responders
before and before
after KSand
treatment.
Interleukin-10
(IL-10), interleukin-6
showing responders
and non-responders
after KS(A)
treatment.
(A) Interleukin-10
(IL-10),
(IL-6),
(B) interleukin-5
chemokine
CXCL10,
and CXCL10,
(C) transforming
growth factor-β
(TGF-β).
interleukin-6
(IL-6), (B) (IL-5),
interleukin-5
(IL-5),
chemokine
and (C) transforming
growth
factor-

β (TGF-β).

2.5. T-Cell Populations Are Not Differential between KS Treatment Responders and Non-Responders
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As
As aa result
result of
of antigenic
antigenic stimulation,
stimulation, T-cells
T-cells undergo
undergo phenotypic
phenotypic changes
changes such
such as
as activation,
activation,
differentiation,
and
proliferation
[31,32].
We
immuno-phenotyped
peripheral
blood
T-cell
populations
differentiation, and proliferation [31,32]. We immuno-phenotyped peripheral blood T-cell
from
participants
KS before
and
treatment
to investigate
whether
T-cellwhether
subsets T-cell
were
populations
from with
participants
with
KSafter
before
and after
treatment to
investigate
+ /CD45RO− (T )], effector
− /CD45RO−
+
−
associated
with
the
KS
treatment
response.
Naïve
[CD197
[CD197
N
subsets were associated with the KS treatment response. Naïve [CD197 /CD45RO (TN)], effector
− /CD45RO+ (T
+
+ (T
−/CD45RO
−
−/CD45RO
+
(T
memory
[CD197
memory
[CD197
)] CD4+ ,
E )], effector
EM )], central
CMmemory
[CD197
(T
E)],
effector
memory
[CD197
(T/hCD45RO
EM)],
central
+ T-cell populations
+ /Human
+/hCD45RO
+ (TCM)] CD4
+, and
and
CD8
were
quantified
by flow
cytometry.
Their
activation
[CD197
CD8+ T-cell
populations
were
quantified
by (CD38
flow cytometry.
+
+
−
−
+
+), senescence
−),
Leucocyte
Antigen/HLA-DR
), senescence
/CD28 /hCD27
), and proliferation
(Ki67−/hCD27
) profiles
Their activation
(CD38+/Human
Leucocyte(CD57
Antigen/HLA-DR
(CD57+/CD28
+
were
also
investigated.
Compared
to
controls,
there
was
an
increase
in
proportions
of
T
(p
=
0.005)
and
and proliferation (Ki67 ) profiles were also investigated. Compared to controls, thereNwas an increase
+
aindecrease
of TEM
(p = a0.001)
in KSofresponders
(Figure(p3A,C,
respectively).
In participants
proportions
of TCD8
N (p = T-cells
0.005) and
decrease
TEM CD8+ T-cells
= 0.001)
in KS responders
(Figures
+ T-cells were comparable to controls +(Figure 3B,D). No changes were noted
with
KS,
T
and
T
CD8
E
CM In participants with KS, TE and TCM CD8 T-cells were comparable to controls
3A,C, respectively).
+ T-cell phenotypes over the course of treatment
in
proportions
CD8
(Figure 3A–D).
Similarly,
none
(Figures
3B,D).ofNo
changes
were noted in proportions of CD8+ T-cell phenotypes
over
the course
of
+T ,T ,T
+
of
the
proportions
of
CD8
,
and
T
at
baseline,
or
after
treatment,
correlated
with
the
KS
N
E
EM
CM
treatment (Figures 3A–D). Similarly, none of the proportions of CD8 TN, TE, TEM, and TCM at baseline,
treatment
responsecorrelated
(Figure 3A–D).
Importantly,
having
high or(Figures
low proportions
CD8+ TN , Thaving
E , TEM ,
or after treatment,
with the
KS treatment
response
3A–D). Importantly,
and
before
and after treatment
no Tsignificant
the treatment
response
highTCM
or low
proportions
CD8+ TNalso
, TE,showed
TEM, and
CM before correlation
and after with
treatment
also showed
no
(Figure
3A–D).
significant correlation with the treatment response (Figures 3A–D).

Figure 3.
3. T-cell
Figure
T-cell population
population (CD8++)) analysis
analysis from
from peripheral
peripheral blood
blood mononuclear
mononuclear cells
cells (PBMCs).
+ +T-cell
T-cell
population
expressing
markers
(A) naïve,
(B) effector,
(C) memory,
effector
PercentageofofCD8
CD8
Percentage
population
expressing
markers
of (A)ofnaïve,
(B) effector,
(C) effector
+ T-cells
T-cells in asymptomatic
controls
and and
responder
and nonmemory,
and (D)
centralCD8
memory
CD8
and
(D) central
memory
in+ asymptomatic
controls and
responder
non-responders
responders
before
and after treatment.
before
and after
treatment.

In the
and TCM
in participants
participants with
with KS were
the CD4
CD4++ compartment,
compartment, proportions
proportions of
of TTNN, TTEM
EM,, and
CM in
+
+
comparable to
to controls
controls (Figures
(Figure 4A,C,D). However, there
there were
were decreased
decreasedCD4
CD4 TET(p
= 0.01)
in
= 0.01)
in KS
E (p
responders when compared to the controls (Figure 4B), but this differential was maintained through
treatment in comparison of the baseline to follow-up (p = 0.04, Figure 4B). There were no
temporal/treatment-associated changes in the CD4+ T-cell phenotypes over the course of treatment
(Figures 4A–D). Similarly, none of the proportions of CD4+ TN, TE, TEM, and TCM at baseline or after
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KS responders when compared to the controls (Figure 4B), but this differential was maintained
through treatment in comparison of the baseline to follow-up (p = 0.04, Figure 4B). There were no
temporal/treatment-associated changes in the CD4+ T-cell phenotypes over the course of treatment
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(Figure 4A–D). Similarly, none of the proportions of CD4+ TN , TE , TEM , and TCM at baseline or
after treatment correlated with the KS treatment response (Figure 4A–D). No significant changes
treatment correlated with the KS treatment response (Figures 4A–D). No significant changes were
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populations of responders and non-responders from pre-treatment or post-treatment time points
(Figure 5 and Supplementary Figures S1 and S2). Overall, despite a demonstrated KS clinical treatment
(Figure 5 and Supplementary Figures S1 and S2). Overall, despite a demonstrated KS clinical
response, the proportions T-cell subsets before and after treatment were not correlative or predictive of
treatment response, the proportions T-cell subsets before and after treatment were not correlative or
the KS treatment response.
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viremia decreased as a consequence of chemotherapy/radiotherapy, which is consistent with the
report by Lin et al. [36]. Additionally, CD4+ T-cell count and HIV-1 viremia did not predict the KS
treatment response. Similarly, a Zambian study on participants with early KS, to evaluate the
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KSHV viremia decreased as a consequence of chemotherapy/radiotherapy, which is consistent with
the report by Lin et al. [36]. Additionally, CD4+ T-cell count and HIV-1 viremia did not predict the
KS treatment response. Similarly, a Zambian study on participants with early KS, to evaluate the
longitudinal response to KS treatment with ART alone, found that HIV-1 viremia and CD4 count before
and after treatment also did not differentiate KS responders from non-responders (Ngalamika et al., in
submission). The lack of outcome association with both CD4+ T-cell count and HIV-1 viremia is also
supported by recent reports of incident KS in individuals with high CD4+ T-cell counts and suppressed
HIV-1 viral load [9–13]. Since our transcriptomic analysis of EpKS lesions revealed no evidence for
HIV-1 transcripts directly in KS lesions (Lidenge et al. in submission), the lack of outcome association
with both the CD4+ T-cell count and HIV-1 viremia could be due to an indirect impact of HIV on
immune function as opposed to simply CD4+ T-cell depletion.
Changes in immune parameters such as CD4+ , CD8+ T-cells, NK, and myeloid derived suppressor
cell populations have been suggested to be biomarkers for lung cancer and non-Hodgkin’s lymphoma
treatment responses [38,39]. CD4+ T-cell help and cytotoxic activity of CD4+ and CD8+ T-cells play an
important role in eliminating infected cells and cancer cells [40]. Poor KS treatment outcomes could
result from reductions in CD4+ TE and CD8+ TEM cells in participants with KS. However, reduction
in CD4+ TE and CD8+ TEM was also evident in responders suggesting possible T-cell qualitative
differentials between responders and non-responders. Unfortunately, whether decreases in CD4+
TE and CD8+ TEM , or the noted increase in CD8+ naïve T-cells corresponded to decreased KSHV
Ag-specific effector functions could not be determined. Assessment of differentials in functionality of
T-cells between treatment responders and non-responders will be important in identifying predictors
of the KS treatment response.
Cytokine dysregulation has often been associated with KS development [41,42]. However,
longitudinal studies of cytokine responses in African participants with KS are lacking. Only a
few studies investigated the role of cytokines in predicting the KS treatment response in US-based
patients [43,44]. In one study, seven patients on ART were treated with rapamycin. Analysis of viral
and immunological parameters revealed no significant changes in plasma KSHV and HIV-1 viral
load, CD4 count, IL-6, and VEGF levels between KS responders and non-responders [43]. Similarly, a
phase II trial of imatinib in participants with EpKS did not find significant association between the
cytokines (IL-6, Rantes, IFN-γ, and basic fibroblast growth factor) analyzed and the KS treatment
response [44]. Despite differences in KS treatment regimens between US and SSA, we consistently
found that the IL-6, plasma KSHV, HIV-1 viral load, and CD4 count are not associated with the KS
treatment response. Importantly, our study has not found significant association of outcome with
any variance in IL-10, IL-5, and CxCL10 that were not previously investigated. However, granulocyte
colony stimulating factor (G-CSF) and hepatocyte growth factor (HGF) were reported to correlate
with the KS treatment response by Tedeschi et al. in a cohort of Italian participants with advanced
EpKS [37]. Unfortunately, incompatibility in assay platforms (Millipore versus BD-CBA) and limited
blood samples from participants with advanced KS prevented us from investigating G-CSF and HGF
in this study. Overall, the Th2 skewing of cytokines we previously reported in pre-treated African
participants with KS did not change significantly despite the demonstrated clinical KS response, and
will not be good markers for the treatment response [25].
In acute viral infections, nAb responses often correlate with protection or control. However, for
Epstein-Barr virus (EBV) and KSHV, high antibody titers are often associated with disease [45,46]. Our
analysis of pre-treatment KSHV-nAb revealed higher prevalence and titers of nAb in both participants
with EpKS and EnKS than in asymptomatic controls [25,30]. In this case, despite decreased KSHV
viremia, total anti-KSHV and KSHV-nAb in participants with KS remained persistently high in both
responders and non-responders. This is similar to the results observed from the analysis of participants
with early KS treated with ART only (Ngalamika et al. in submission). It is possible that the high
KSHV-humoral responses result from continued production of antibody-associated cytokines IL-6,
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IL-5, and IL-10 evident in both studies, even though the Ab response does not appear to contribute to
KS control.
It is puzzling that none of the immune parameters assessed predicted KS treatment response
despite the strong association between KS and immune suppression. Furthermore, it was noted that a
reduction in size and number of KS lesions after treatment did not correlate with the magnitude of the
immunological responses measured to date. This implies that the response requires modulation of
the qualitative or functional aspects of immune control. The lack of significant changes potentially
explains the short-lived clinical responses and high recurrence rates reported in other studies [13,21].
As suggested by Roshan et al., weak, and individualized T-cell functional responses (IFN-γ) against
KSHV, coupled with a lack of immunodominant epitopes, seem to be common features in participants
with KS and in asymptomatic controls [47]. It is possible that differences between treatment responders
and non-responders lie in the differences in the T-cell functional repertoire against KSHV and KS.
Other host factors such as the HLA type or efficiency of viral/tumor Ag presentation may also play a
role in determining the response to treatment in participants with KS. Further functional studies over
the course of treatment will be essential to define relationships between host factors and functional
T-cell responses that determine the KS treatment outcome. The extent of KS disease prior to initiation
of treatment appears to be more important than viral and immunological parameters assessed later in
the disease.
A limitation of our study is the small sample size. The stringent recruitment criteria to ensure that
only confirmed KS cases are analyzed has limited our sample size and, hence, the depth of our analyses.
Thus, it is unlikely that subtle immunological differences between the treatment responders and
non-responders can be detected. Additionally, late disease presentation due to the lack of mechanisms
for identification of early KS, together with losses during follow-up, have limited our sample size and
the depth of our investigations. Larger studies with close patient follow-up are warranted to fully
characterize viral and immunological factors associated with the KS treatment response. However, this
study highlights the fact that immune dysregulation in participants with KS persists despite a reduction
in size and number of lesions in some participants. Additionally, the tested viral and immunological
parameters did not predict the KS treatment response in SSA.
4. Materials and Methods
4.1. Study Design, Subjects, and Samples
The cohort was comprised of 26 study subjects who were ≥18 years of age and of both genders
from Ocean Road Cancer Institute (ORCI), Dar es Salaam including 13 participants with KS and
13 KSHV-infected asymptomatic controls. Seven of the controls were HIV-1+ and six were HIV-1− .
Consenting subjects with complete clinical and treatment information were recruited. Only participants
with KS who were newly diagnosed, histologically confirmed, and KS biopsy KSHV-DNA PCR positive
at baseline were included. This is to avoid the approximately 35% misdiagnosed cases resulting from
only clinical and/or histopathology diagnosed cases in SSA [48,49]. Peripheral blood samples were
collected at baseline and at 3–12 months post-therapy cessation. Plasma was HIV-1 tested and the
KSHV viral load was quantified by real-time PCR. KS tumor biopsy samples (4 mm) were collected
(baseline only). All study procedures were approved by the institutional review boards from the
Tanzania National Institute for Medical Research, Ocean Road Cancer Institute, and the University of
Nebraska-Lincoln (UNL), IRB number: 20141014709FB.
4.2. Kaposi’s Sarcoma Response Criteria
According to ORCI treatment guidelines, all participants with EpKS, who were not on ART, began
ART immediately after diagnosis. Depending on the extent of KS disease, patients are then treated with
combined chemotherapy consisting of six cycles of adriamycin, bleomycin, and vinblastine/vincristine
(ABV) or radiotherapy (XRT). In this study, the KS treatment response was determined 3 months after
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completion of ABV chemotherapy or XRT. Some KS treatment responders maintained their remission
status up to 12 months after completion of treatment. A responder was defined under the AIDS Clinical
Trial Group (ACTG) clinical response criteria for a complete and partial response while non-responders
included stable and progressive disease [50]. For statistical analysis, all patients were defined as either
responders or non-responders. In cases where patch, plaque, and nodular KS lesions existed in the
same patient, the most advanced KS lesion was used to define the lesion morphotype.
4.3. HIV-1 Status and HIV-1 and KSHV Quantification in Plasma and Tumor Tissues
HIV-1 infection status and quantification of plasma HIV-1 viral load before and after treatment
were performed as previously described [25]. Extraction of KSHV viral DNA from plasma, and KS
tumor biopsies followed by real-time PCR amplification of KSHV-ORF26 were conducted as previously
described [25].
4.4. rKSHV.219 Production, KSHV Serology, and Neutralization Assays
The rKSHV.219 was generated and tittered on HEK293T cells as previously described [25,51].
Levels and titers of the KSHV antibody (Ab) and neutralizing antibody (nAb) were determined as
previously described [25]. Heat inactivated plasma was incubated at 1:50 dilution with rKSHV.219
at 37 ◦ C for one hour. A virus-plasma mixture was used to infect HEK293T cells at 37 ◦ C for 72 h.
Flow cytometry was used to quantify infection. Plasma samples demonstrating >50% inhibition of
infection compared to a negative control plasma were categorized as neutralizing. All samples that
were KSHV-nAb positive at the 1:50 dilution were re-assayed in two-fold dilutions of plasma from 1:50
to 1:800 to define the 50% inhibitory concentration (IC50 ).
4.5. Multiplex Bead-Based Immunoassay
Plasma cytokines and chemokines were quantified with Becton-Dickinson Cytometric-Bead-Array
(CBA) FlexSet kits, according to the manufacturer’s protocol. The standard sensitivity array
(picograms/mL) included interleukin-4 (IL-4), chemokine CxCL10, interleukin-5 (IL-5), and
transforming growth factor-β (TGF-β). The enhanced sensitivity array (femtograms/mL) included
interferon-G (IFN-G), interleukin-1β (IL-1β), interleukin-6 (IL-6), interleukin-12p70 (IL-12p70),
interleukin-17A (IL-17A), interleukin-10 (IL-10), and tumor necrosis factor- α (TNF-α). Raw data were
collected on an Accuri C6 Plus cytometer (BD-Biosciences, San Jose, CA, USA) and analyzed with
FlowJo version-10 (TreeStar, Ashland, OR, USA).
4.6. Flow Cytometry
To immunophenotype cell populations, PBMC were thawed, washed, split into two panels, and
stained for 10 min in the dark at room temperature with antibodies against the following human surface
markers: CD3 Percp.Cy5.5 (BD-Biosciences, San Jose, CA, USA), CD4, CD8-FITC, CD45RO-APC,
CD197-AlexaFluor-700, CD38-BV510, HLA-DR-PE.Cy7, CD28-BV711, CD27 PE-Dazzle-594, CD57-APC,
and CD107a BV421(Biolegend, San Diego, CA, USA). The cells were fixed using Perm/fix
(BD-Biosciences, San Jose, CA, USA) for 20 min at 4 ◦ C in the dark, and then stained for intracellular
Ki67 (Biolegend, San Diego, CA, USA) or IFN-γ (Biolegend, San Diego, CA, USA). Raw data were
quantified by FACSAria (BD-Biosciences, San Jose, CA, USA) and analyzed with FlowJo version-10.
4.7. Statistical Analysis
Viral nucleic acid detection in plasma, antibody, and cytokine responses as well as T-cell
immunophenotypes were stratified into high and low levels before and after KS treatment. Correlation
with the treatment response was analyzed. One-way analysis of variance with Tukey’s multiple
comparison test and non-parametric Mann-Whitney t-test were employed to determine differences
between groups. One control group was (KSHV+ /HIV-1+ ) similar to EpKS patients in order to control
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for viral co-infection and investigate the effect of cancer (KS) in the background of HIV-1 co-infection
on T-cell phenotypes while the other group of controls was (KSHV+ , HIV-1− ) similar to EnKS patients
in order to control for KSHV infection and investigate the effect of cancer (KS) in the absence of
HIV-1 co-infection on T-cell phenotypes. Similar analyses on cytokine and antibody responses have
been reported previously [25]. The effect of the variables as predictors of KS treatment response was
determined by logistic regression using SAS version 9.4 software (SAS Institute, Cary, NC, USA).
GraphPad Prism v5 (GraphPad Software, San Diego, CA, USA) was used for statistical analyses. All
tests were 2-tailed, and p-values < 0.05 were considered significant.
5. Conclusions
In summary, there was a trend toward favorable treatment outcomes in patch and plaque stages
of KS. Our study tested KSHV and HIV-1 viremia, CD4 T-cell counts, KSHV-humoral responses,
various cytokine responses, and the magnitude of T-cell population subsets as predictors of the KS
treatment response but did not find significant associations. An important finding of this study is
that, despite favorable clinical responses in some participants with KS, immunological dysregulation
observed at baseline, persisted in these patients in remission, and this likely contributes to the high KS
recurrence rates.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/6/1594/s1.
Figure S1: T-cell population analysis from peripheral blood mononuclear cells (PBMCs). Figure S2: T-cell
population analysis from peripheral blood mononuclear cells (PBMCs).
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